fda glp-1 warning october 2025 What Patients Need to Know About the Policy Changes GI Adverse Effects of Glucagon-Like

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications originally developed for type 2 diabetes management and, more recently, approved for weight management

(2021) Frontiers in Pharmacology | Zeisel, S.: A brief history of choline

Patients with severe gastrointestinal diseases such as gastroparesis and inflammatory bowel disease should avoid GLP-1 analogs, and these medications are not recommended for patients with certain genetic predispositions

Pre-trial experimentation had shown that commencing perfusion at a physiological pH resulted in alkalotic overshoot, which was not possible to treat without permitting pCO 2 to rise

If youre not sure which lever is your main one, a few tests can clear it up